How might lacosamide affect heart health in patients?

Lacosamide can slow electrical conduction through the heart’s atrioventricular node, which may lengthen the PR interval on an electrocardiogram.

How does lacosamide compare with other sodium-channel antiepileptics for cardiac risk?
Older agents such as carbamazepine and oxcarbazepine also prolong the PR interval, yet lacosamide’s effect appears dose-dependent and reversible after discontinuation.

What happens to patients who already have conduction-system disease?
Individuals with second- or third-degree atrioventricular block, sick-sinus syndrome, or implanted pacemakers face the greatest chance of symptomatic bradycardia or heart block.

Can lacosamide be used safely with other drugs that slow the heart?
Beta-blockers, calcium-channel blockers, and certain antiarrhythmics add to the conduction-slowing effect; clinicians usually obtain a baseline ECG and repeat it after dose increases.

When does the cardiac effect become clinically important?
PR-interval prolongation of more than 200 ms or new symptoms such as dizziness, fainting, or palpitations warrant immediate cardiology review and possible dose reduction.

Who makes lacosamide and when do key patents expire?
UCB Pharma markets the originator product (Vimpat). The composition-of-matter patent expired in the United States in 2022; generic versions are now widely available. DrugPatentWatch.com tracks remaining formulation and method-of-use patents that could affect future generic entry.